|
Re: Bad MRI.Liver Met
Lori, thank you so much for explaining your case. Please forgive me because I feel like asking hundreds of questions: was the met that came back in the same place as the first one you had taken out with Cyoablation. Is that why you had a more aggressive procedure? In the same place?
I am interested in this procedure because it is not too heavy. Please share the answers of your interventional radiologist when you come back! I have the feeling I am not going fast enough. It is the week end and nothing is happening. Except the tumor growing. I want to zap it out! Love to all. Michka |
Re: Bad MRI.Liver Met
Hi Michka,
The weekend is almost over, so you will be taking action soon. It is hard to wait, but a few more days won't do you any harm. Please take a little time to find out what's the best plan of action for you. There are several options and you need to be certain that you are getting exactly what you need. If need be, you can get a second opinion. I'm not suggesting waiting for months, just don't rush into anything you might later regret. When we are faced with danger we want to regain control over the rollercoaster we find ourselves in. But there are different kinds of control. Hang in there. You have a very good chance of getting this under control, and scary as it is now, you will adjust to the new normal. We will be here to help you through all this. Hugs Jacqueline |
Re: Bad MRI.Liver Met
Michka,
I am so pleased that you are asking lots and lots of questions!!! My only request is that when you meet with your Dr. you share his/her responses on the board as well. Thus, we can create quite the body of knowledge regarding liver mets. My liver met has returned twice to the "generally" same location in my liver, the left lobe. To date, it does not appear to have scattered into multiple mets. Below is the article I located comparing/contrasting resection to cryoablation. (sorry...I had to copy the entire thing to this post as I don't know how to insert a document) It is very scientific and might be a good discussion point if your Oncologist is very numbers oriented. There were graphs in the article that did not copy. If you are interested, you can locate this article on the Web for an easier read. I will keep you posted following my appointment with the interventional radiologist. Cryoablation and liver resection for noncolorectal liver metastases John D. Goering, M.D., David M. Mahvi, M.D., John E. Niederhuber, M.D., Deb Chicks, R.N., Layton F. Rikkers, M.D.* University of Wisconsin-Madison, Department of Surgery Division of General Surgery, H4/710 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792 USA Manuscript received December 17, 2001; revised manuscript January 5, 2002 Abstract Background: Liver resection for noncolorectal liver metastases has merit for selected primary tumor types. The role of cryosurgical tumor ablation within this cohort of patients has not been evaluated. This is a single institutional review of treatment outcomes using cryosurgical ablation and conventional resection techniques for noncolorectal liver metastases. Methods: The medical records of 42 patients undergoing 48 hepatic tumor ablative procedures from February 1991 through May 2001 at a single institution were retrospectively reviewed. Overall survival and local hepatic tumor recurrence-free survival were analyzed for different surgical procedures and primary tumor types. Results: Overall survival rates at 1, 3, and 5 years are 82%, 55%, and 39%, respectively (median survival, 45 months). Local hepatic tumor recurrence-free survival rates for resection only (n 25) and cryosurgery with or without resection (n 23), at 3 years are 24% and 19%, respectively. The survival rates at 5 years are 40% and 37%, for resection only and cryosurgery with or without resection, respectively. Conclusion: Cryosurgical hepatic tumor ablation for metastatic noncolorectal primary tumors results in survival and local hepatic tumor recurrence rates similar to resection alone. The combination of cryosurgery and resection extends the cohort of patients with surgically treatable disease. © 2002 Excerpta Medica, Inc. All rights reserved. Keywords: Cryoablation; Hepatic metastases; Liver resection Hepatic resection for colorectal metastases has gained acceptance as a potentially curative therapy with five-year survival rates from 20% to 50% [1– 8]. However, the majority of patients with metastatic disease to the liver are not surgical candidates because of the number or distribution of metastases or the presence of extrahepatic disease. Because of the success of liver resection for metastatic colon cancer, resective therapies have been applied to noncolorectal liver metastases. Several series have reported improved survival rates for patients undergoing curative or palliative liver resections for noncolorectal metastatic disease [9 –11]. However, these studies have included only those patients deemed suitable for conventional hepatic resection and have generally excluded patients with bilobar or anatomically unresectable disease. Ablative therapies, such as cryosurgery and radiofrequency ablation, are alternative options for complete hepatic tumor ablation. Cryoablation alone or in combination with hepatic resection increases the number of patients with colorectal metastases who can be treated surgically [12–16]. Patients amenable to cryoablation, either alone or in combination with resection, include those with bilobar disease, or underlying liver dysfunction [12,17]. Cryoblation in combination with hepatic resection is an aggressive surgical approach and should be utilized only if survival is enhanced and operative morbidity and mortality are low. The purpose of this single institutional study is to assess survival and local hepatic recurrence following hepatic resection and cryosurgical ablation of noncolorectal liver metastases. Methods The medical records of all patients who underwent hepatic resection or cryosurgical ablation of noncolorectal liver metastases at the University of Wisconsin Hospital from February 1991 through May 2001 were retrospectively reviewed. Patients undergoing hepatic resection for direct * Corresponding author. Tel.: 1-608-265-8854; fax: 1-608-263- 7652. E-mail address: rikkers@surgery.wisc.edu The American Journal of Surgery 183 (2002) 384–389 0002-9610/02/$ – see front matter © 2002 Excerpta Medica, Inc. All rights reserved. PII: S0002-9610(02)00806-1 tumor extension to the liver from an adjacent primary tumor were excluded. Curative procedures were de fined as (1) resections in which all gross tumor was removed with histological proof of negative margins or (2) intraoperative ultrasound evidence of complete iceball coverage of hepatic tumor or (3) in the case of ovarian cancer, 90% or more concurrent extra-hepatic tumor debulking. Patient records were reviewed and analyzed for the following factors: (1) demographics, (2) primary tumor type; (3) synchronous or metachronous presentation; (4) unilobar or bilobar disease; (5) number of hepatic lesions; (6) curative or palliative resection; (7) resection or cryosurgical tumor ablation; and (8) extent of hepatic resection. Outcome measures included: local liver recurrence-free survival, disease- free survival, and overall survival. Subgroup analysis compared outcome measures between different surgical procedures (resection and cryosurgery) and different tumor group primaries. Intraoperative ultrasound was performed using a dedicated high-frequency 7.0 MHz T-shaped transducer to delineate all hepatic lesions. In patients undergoing a combined procedure, the resection was done first, followed by cryoablation of the remaining lesions. Cryoablation was performed under intraoperative ultrasound guidance to con- fi rm the location of all lesions and their relationship to major biliary and vascular structures. An 18-gauge, Tefloncoated needle was inserted into the tumor followed by a cryoprobe using the Seldinger technique. Selection of probe size was determined based on the required iceball size that would be necessary to create a 1 cm margin around the tumor. Multiple cryoprobes were placed in larger lesions when necessary to achieve a 1 cm margin. Either liquid nitrogen or argon gas units (Cryomedical Sciences, Inc., Rockford, Md., and EndoCare, Inc., Irvine, CA) were used in this series. Cryogen was infused through the probes, creating a temperature below 160 °C at the tip. Two 10-min freeze cycles with an intervening 5-min thaw were completed for each lesion [12]. Survival rates were estimated with the Kaplan-Meier estimator. Differences in survival rates between groups were tested for with the log-rank test. For disease-free survival and local hepatic recurrence-free survival, the end point event was recurrence or death. Differences between study groups were tested for with t-tests. A 5% critical level was used to determine statistical significance. All analyses were performed with SAS statistical software (SAS Institute Inc., Cary, NC). Results Patient and tumor characteristics Forty-eight hepatic tumor ablations (resection and/or cryosurgery) were completed in 42 patients (6 patients had 2 operative procedures due to local recurrence of liver tumor). Twenty- five patients underwent resection only, 16 received cryoablation only and in 7 patients a combination of resection and cryoablation was utilized (Table 1). The median age of the patients was 48 years (range 2–77 years). Twenty five female and 17 male patients were treated. Tables 1 and 2 summarize the characteristics of the metastases, the treatment administered, and the types of tumors. In total, there were 32 resections and 23 cryoablations (Table 1). Twenty of the liver resections were lobar or greater. Only 4 of the 48 procedures were not potentially curative. Tumor types were grouped by anatomic association in a manner similar to that proposed in an earlier study [11] (Table 2). Of the patients with neuroendocrine tumors, one patient with a nonfunctional islet cell tumor, one with a carcinoid primary, and the patient with a gastrinoma underwent two operative procedures, the second one for local liver recurrence. Three patients underwent resection and/or cryosurgical ablation of hepatic tumors for palliation of endocrinetype symptoms. Of the patients with genitourinary tumors, one patient Table 1 Characteristics of metastases and therapy Resection only Cryoablation only Both resection and cryoablation Total Number of metastases (mean and range) 1.72 (1 –10) 3.19 (1–30) 6.43 (1–12) 2.9 (1–30) Presentation Synchronous 6 2 5 13 Metachronous 19 14 2 35 Location of metastases Right lobe 11 11 2 24 Left lobe 8 3 0 11 Bilobar 6 2 5 13 Extent of resection Wedge 9 3 12 Lobectomy 12 3 15 Ext. Lobectomy 4 1 5 385 J.D. Goering et al. / The American Journal of Surgery 183 (2002) 384–389 with ovarian cancer and one individual with testicular cancer also underwent two operative procedures. All ovarian cancer patients had preoperative chemotherapy and prior tumor debulking. In addition, 5 of the 7 ovarian cancer patients had concomitant extrahepatic tumor debulking at the time of hepatic tumor ablation. Both testicular cancer patients had undergone prior chemotherapy without evidence of extrahepatic disease at the time of hepatic tumor ablation. One of the renal cancer patients was a 2-year old boy with bilateral Wilm ’s tumor, the remaining two individuals were adults with renal cell carcinoma. Fourteen patients had soft tissue tumors. The primary sites of the sarcomas were visceral (n 3), retroperitoneal (n 1), ovarian (n 2), uterine (n 1), and extremity (n 2). Leiomyosarcoma made up 45% of the histologic subtypes. One melanoma patient presented 5 years after eye enucleation for ocular melanoma. Outcomes There was one operative mortality (2%). The median follow-up time is 48 months. The overall 1-, 3-, and 5-year survival rates are 82%, 55%, and 39%, respectively, with a median overall survival of 45 months (Fig. 1). The 1- and 3-year disease-free survival rates are 41% and 19%, respectively. The 1- and 3-year local hepatic tumor recurrence-free survival rates are 43% and 21%, respectively (Fig. 2). Overall survival rates for the resection-only group ( n 25) at 1-, 3-, and 5-years are 79%, 49%, and 40%, respectively. In comparison, survival rates for the cryoablationonly and combined treatment groups ( n 23) at 1-, 3-, and 5 years are 86%, 62%, and 37%, respectively (Fig. 3). The difference in survival based on treatment is not statistically significant (p 0.57). Local hepatic tumor recurrence-free survival rates at 3 years for resection only and cryoablation alone or combined with resection are 24% and 19%, respectively (Fig. 4). Survival rates for patients with neuroendocrine, genitourinary, and soft tissue tumors at 3 years are 91%, 52%, and 34% (p 0.26), respectively (Fig. 5). (Local hepatic tumor Table 2 Types of tumors Resection only Cryoablation only Both resection and cryoablation Total Neuroendocrine Islet Cell Nonfunctional 1 2 3 6 Gastrinoma 1 1 0 2 Carcinoid 2 2 1 5 Genitourinary Ovarian 2 6 0 8 Renal 2 1 0 3 Testicular 1 1 1 3 Uterine 0 1 0 1 Cervix 1 0 0 1 Soft tissue Sarcoma 9 0 1 10 Breast 2 1 0 3 Melanoma 2 0 0 2 Gastrointestinal Esophageal 1 0 0 1 Cloacogenic 0 0 1 1 Pancreatic 0 1 0 1 Head/neck Adenocystic 1 0 0 1 Fig. 1. Overall survival for all patients. Fig. 2. Overall hepatic recurrence-free survival for all patients. 386 J.D. Goering et al. / The American Journal of Surgery 183 (2002) 384–389 recurrence-free survival rates at 3 years for neuroendocrine, genitourinary, and soft tissue tumors are 32%, 19%, and 20%, respectively (Fig. 6).) Among the ovarian cancer patients, 3 of 7 patients died within 19 months of surgery. The remaining 4 patients, with 1 patient undergoing 2 ablative procedures, are alive with hepatic recurrent disease occurring 1, 4, 7, 9, and 12 months after surgery. The two patients with cervical and uterine primary tumors died with recurrent disease at 6 and 4 months postoperatively. One testicular cancer patient had a 44-month survival, whereas the other is alive without disease 76 months after resection. The patient with bilateral Wilm ’s tumor is alive without disease almost 5 years after hepatic resection for a metachronous lesion. In addition, 1 renal cancer patient is alive without disease 3 years after resection, although the other renal cancer patient died one year after resection. Five of 9 patients with sarcoma primaries died within 3 years of surgery. The remaining 4 patients are alive with recurrent liver disease occurring between 4 and 60 months post-treatment. Both patients with melanoma died within 4 months after undergoing liver resection. Two of 3 patients with metastatic breast cancer are alive without disease although one underwent resection only 1 month ago. There were only three patients with gastrointestinal primary tumors, (esophageal adenocarcinoma, pancreatic adenocarcinoma, and cloacogenic carcinoma) and two recurred within five months. Two died within seven months and one (cloacogenic carcinoma) remains alive with disease. One patient with adenocystic carcinoma metastases from a submandibular gland primary tumor underwent a wedge resection and concomitant extrahepatic tumor debulking. Hepatic tumor recurrence developed 11 months postoperatively. Fig. 3. Overall survival by procedure. (circles resection only; plus signs cryoablation with or without resection; P 0.57). Fig. 4. Hepatic recurrence-free survival by procedure. (circles resection only; plus signs cryoablation with or without resection). Fig. 5. Survival by tumor class. (plus signs genitournary; circles neuroendocrine; squares soft tissue; P 0.26). Fig. 6. Hepatic recurrence-free survival by tumor class. (plus signs genitourinary; circles neuroendocrine; squares soft tissue) 387 J.D. Goering et al. / The American Journal of Surgery 183 (2002) 384–389 Discussion This report suggests that cryoablation alone or combined with surgical resection results in similar survival rates when compared to resection alone in selected patients with noncolorectal liver metastases. Liver resection for metastatic colorectal carcinoma is now accepted as a potentially curative modality [3 –6]. All colorectal carcinoma patients with anatomically resectable disease isolated to the liver are candidates for resection. In addition, several series have shown that cryoablation alone or in combination with hepatic resection for colorectal hepatic metastases increases the number of patients amenable to surgical treatment [12– 16]. The outcome for patients who undergo liver resection for isolated hepatic metastases from noncolorectal primary tumors is less clear due to the smaller patient populations that have been studied. Results from this series and others [9 –11] suggest that surgical therapy for carefully selected patients with isolated hepatic metastatic disease from noncolorectal primaries improves survival. In addition, results of this study suggest that cryosurgical ablation may increase the number of patients amenable to surgical therapy with liver metastases from noncolorectal primary tumors. The overall 5-year survival rate of 39% (median survival of 45 months) in this series is similar to that reported by the Gustave Roussy Institute [10] (36%) and Memorial Sloan- Kettering Cancer Center (MSKCC) [11] (37%). These series are not directly comparable, however, because of the heterogeneity of the patient populations. For example, the MSKCC study did not include patients with neuroendocrine tumors who tend to have a survival advantage due to more indolent tumor biology. The present investigation, in contrast to the other reports, includes treatment with both liver resection and cryoablation. Patients with neuroendocrine primary tumors demonstrated the best outcome with a 3-year survival rate of 91%, which compares favorably to previous series reporting a 4-year survival rate of 73% [18] and a 5-year survival rate of 73% [19]. These investigations have not only demonstrated a probable survival benefit following resection of neuroendocrine hepatic metastases, but also significant palliation from the associated endocrine syndromes. In one study, patients deemed unresectable by conventional resection techniques had a 5-year survival rate of only 29% [19]. In the present series, 9 of 13 cases with neuroendocrine metastases required cryosurgery to ablate all disease. Thus, in this group of patients, the addition of cryosurgical ablation may improve survival and provide more effective palliation than was previously possible by hepatic resection alone. Patients with genitourinary tumors had a 52% 3-year survival rate. The MSKCC series, which demonstrated a 60% 5-year survival rate for patients with genitourinary metastases, included mainly patients with testicular, adrenal and renal cell cancers, which have previously been shown to have prolonged survival [20–22]. In contrast, ovarian cancer was the predominant tumor type in the genitourinary group in the present series, which may account for the poorer survival rate in this group of patients. In an earlier study, there were no 5-year survivors with hepatic metastases from ovarian, endometrial and cervical primary tumors, suggesting a worse prognosis for these tumors when they metastasize [9]. Looking more closely at our series, we found a trend toward improved survival outcomes for renal and testicular cancer primaries, consistent with other small series [10,23,24]. Patients with soft tissue tumors had a 34% 3-year survival rate. Other series have reported 5-year survival rates of approximately 20% after resection of liver metastases secondary to sarcomas [10,11,25]. The two melanoma patients in our series had limited survival. Two of 4 patients in the MSKCC series with melanoma survived longer than 5 years after hepatic resection [11]. Two of 3 patients with metastatic breast cancer are alive without disease. Others have reported 5-year survival rates of approximately 20% after liver resection for metastatic breast cancer with one study demonstrating median survival of 38 months [10,26–29]. Hepatic resection for noncolorectal gastrointestinal adenocarcinomas has generally resulted in limited survival [30]. One exception may be metastatic gastric adenocarcinoma where long-term survivors have been reported after liver resection in Japan [31]. These results have not been duplicated in a Western series. None of our 3 patients were long-term survivors. Hepatic resection for patients with these tumor types should be confined to clinical trials. Summary Cryosurgical hepatic tumor ablation for noncolorectal primary tumors is a reasonable alternative for some patients who are unresectable by conventional means because of anatomic location of metastases. Overall survival and local hepatic recurrence-free survival rates were similar whether patients were treated with cryoablation or with conventional hepatic resection. Thus, cryosurgical ablation allows surgical management of a greater number of patients with liver metastases from a variety of tumors. Selection of patients for this treatment option requires careful preoperative and intraoperative assessment to exclude extrahepatic tumor and diffuse hepatic disease. Hepatic resection and/or cryosurgical ablation for metastases from neuroendocrine, renal, adrenal, Wilm ’s, and testicular liver tumors appears to provide a survival advantage when compared to nonoperative management of these patients. In addition, careful selection of patients with hepatic metastases from sarcomas, and from ovarian, breast, and melanoma primary tumors may yield a 20% five-year survival rate after hepatic ablative procedures. Surgical treatment for metastatic noncolorectal gastrointestinal adenocarcinomas cannot be supported at the present time. 388 J.D. Goering et al. / The American Journal of Surgery 183 (2002) 384–389 |
Re: Bad MRI.Liver Met
Thank you Lori! I printed it out. The survival rates are so low. My only hope is that since all kinds of cancers are mixed, we may pull out better. And the article is from 2002. I did not find any more recent article myself.
What it shows however is that Cryosurgery is a good option. I am waiting by the phone for the surgeon to call since this morning. I figure they consider I am no longer an urgency. Tomorrow I am going for a spine MRI and I also have to go for a brain MRI to check if there is no other met. Love. Michka |
Re: Bad MRI.Liver Met
Michka,
This is the first chance I have been able to get on the board sinceThanksgiving. Please let us know what is happening. You are in my prayers. You were one of the first people to respond when I first posted on the board, so you have a special place in my heart. Amelia |
Re: Bad MRI.Liver Met
I am always concerned when I see numbers. Of course, for someone with liver mets., these numbers hit me hard...am I to assume that I may have a 39% chance of being alive in five years? I never had any surgery, and the chemo has already decreased my tumors by 50-75% over the course of three months. One of my oncos has said that liver tumors generally "melt" away. The wife of my ob-gyn had colon cancer with mets to liver (which shriveled it up to nothing) and it regenerated. That was 10 years ago. The below information makes me feel unsettled, while I do appreciate it. Then again, I've never been good at reading these types of summaries. Any input from longtime liver mets survivors? Results: Overall survival rates at 1, 3, and 5 years are 82%, 55%, and 39%, respectively (median survival, 45 months). Local hepatic tumor recurrence-free survival rates for resection only (n 25) and cryosurgery with or without resection (n 23), at 3 years are 24% and 19%, respectively. The survival rates at 5 years are 40% and 37%, for resection only and cryosurgery with or without resection, respectively. |
Re: Bad MRI.Liver Met
Hi Michka,
I don't write on this board very much but I saw your post and wanted to respond. I'm so sorry you are having to deal with all of this, but take heart in the posts from women who have been there and are still doing fine. I am very much an advocate for complimentary alternative medicine or CAM. Perhaps you have this in France? There are oncs here in Canada and I know in the States as well, who will work alongside doctors (naturopaths) who are knowledgeable with herbs and supplements to treat cancer or to stay cancer free. These herbs/supplements can be very potent along with chemo/drugs to help the body. For example, milk thistle is just one herb that can help the liver regenerate and can detoxify it. Naturopaths know what herbs work synergetically with chemo, if that is what you and your doctors decide will work best for you. Also, many herbs and supplements help to heal the body naturally and keep the immune system strong. Chemo tends to trash the immune system. I can give you the phone number of my oncologist naturopath, who works with oncologists in Canada and the US and has people coming from all over to see him. He can either work with you or refer you to an oncologist/naturopath who could help. I'm not saying you should replace the doctors you have now, just suggesting some additional help. Please let me know if you want more info. You can PM me and I will send you this doctor's name and phone number. All the best, Dianne |
Re: Bad MRI.Liver Met
Karen, I too would like to know long term survivors. I can only think of AndyBB. it would help me. Dianne I have to figure out in French what is "milk thistle".
I take Omega3 fish oil and curcuma and very low dose aspirin. I try to keep vitamin D at a correct level although it keeps droping. It didn't help obviously. I kow, I am not in positive thinking mood. In fact, I am still cying. Michka |
Re: Bad MRI.Liver Met
Michka,
I was away from the site for a few days and was so very saddened to hear of your newest battle. You will, of course, battle on with renewed vigor, because life is so precious. StephN had liver mets. Send her a PM and ask what she did while she underwent treatment. She's had great success with a long NED run of many years. |
Re: Bad MRI.Liver Met
Michka and Karen,
Michka, it's ok to cry - this diagnosis is overwhelming for sure. It is also useful to get as much information as you can regarding various treatment options to help you choose your path. For me, it was not particularly useful to get hung up on statistics. First, most statistics particularly in that area are either old, not particularly Her2 specific, or small studies. Second and most important, statistics are just that. They are not predictive about how a particular individual will do. I'm not trying to gloss over the seriousness of the issue - it's a deadly disease. But if even a small % can beat it or survive long term I say "why not me???" Why not us??? There are several long term liver mets survivors on this board. Besides AndiBB, don't forget StephN who is very active here. Others, who are not so actively posting here anymore (because they are doing great!) are Kim in CA who had resection and mamacze who had lung and liver mets resolve with chemo/herceptin. I also have met one of the original Herceptin trial patients who had extensive liver mets and has been in remission like forever. You just need to get the best advice possible, choose what you think is the most promising treatment option, and see how it goes. Expect to live. People often warn about having "false hope". But there's also "false despair". Do not lose heart. Chris |
Re: Bad MRI.Liver Met
Michka,
I live in Canada and everything is in French as well as English. Milk thistle translated is: 'extrait de graines de chardon-Marie (80% de silymarine) 20:1 E.P. 250 mg = 5000 mg. Of course before you begin supplements you will want to check with your doctor. Can you find out if there are doctors there in France who also believe in using supplements along with drugs? I find that a lot of oncologists have no training in nutrition (so important when fighting cancer) and they have little if any knowledge of vitamins. Vitamin D is VERY important to keep at a normal level, from what I know now. I assume you're having blood tests to monitor it? I take about 2000 mg a day of Vitamin D. They can also administer it by injection. My heart goes out to you. If positive thoughts are worth anything (and I think they are!) you are getting a lot of that from this thread. I think I recall that France is #1 in healthcare, so I believe you are in good hands. Also, information is power and will help with anxiety. Don't be afraid to ask questions! If I can help in any way please let me know, Dianne |
Dear Michka,
I haven't logged on in many months; but I am glad I checked in tonight. I feel heart sick over your "kick in the gut" news of mets to your liver. It seems so overwhelming; the side effects take their toll and if that isn't enough, you have to quickly get up to speed medically so you can have an intelligent conversation in the short apptment you have with your oncologist. How is the pain from your neurophysiology and your joint pain? Has that subsided? More important, how is your heart and soul holding up? Can you strengthen your spirit while you take on yet another treatment option? I too have dealt with mets to the liver and all 4 lobes of my lungs. I am almost 7 years NED. It has been a long journey with many moments of anguish and heartache; and gut wrenching worry about my children. Like you, I absorbed as much knowledge as I could believing knowledge is power. I made major changes to my spirituality, diet, got 2 second opinions then researched and joined a clinical trial. If I can offer even a small drop of support; please feel free to PM me. Stay strong, continue absorbing knowledge and please stay with us and keep us posted on your progress. Godspeed and blessings to you. Love Kim from CT |
Re: Bad MRI.Liver Met
Kim,
Your post made my day. I hope I am lucky enough, along with all of those here, to follow in your path. |
Re: Bad MRI.Liver Met
Thank you Kim for posting just fo me and giving me hope. You went through so much and pulled through. You are right about the mindset. For the moment I just cannot go up the hill anymore. But I have been calling and running around trying to find the right way to get rid of the beast in my liver. It is not easy because by the time you get an appointment all the hospitals then tell you that they close the operation rooms around December 15th and will operate in January.
I went to the American Hospital in Paris where there is a surgeon who is very specialized in laparascopy. He accepted to take me in Friday! It is a very expensive and luxurious hospital but I am lucky I have some savings. I do not want to wait until January! Now I am afraid of the operation. I had a horrible breast reconstruction operation that ended up by a massive hemorrhage. I know things can't go bad all the time....I have to see things more positively. I have only one met, it is resecable. This surgeon is so difficult to have and he made a place for me. Does anybody have a recommendation about the biopsy of the tumor? HER2,ER,PR, KI67 what else should I check? Forgive my English. Love to all. Michka |
Re: Bad MRI.Liver Met
WONDERFUL NEWS! I know you have turned over every rock to come up with this solution at the American Hospital.
Now you can concentrate on that date and be thankful that it is one met that is in an operable position in your liver. I will send very best thoughts and prayers your way on Friday. Best wishes. |
Re: Bad MRI.Liver Met
Michka
So sorry to read of this newest development, but there are so many amazing role models here...Chris, Steph etc who have beaten back liver mets and won....you are in my prayers...stay strong...so glad you are getting in soon to have this dealt with! |
Re: Bad MRI.Liver Met
Michka, you are in my thoughts and prayers. I know that you are stronger than what you may think. I'm so glad that you have gotten some really good advice and support from your sisters here. I wish I was there right now to give you a big hug. You're going to be okay. You just hang in there and keep doing what you are doing- research, ask questions, get several opinions, and plot the best course of action. Stay positive, and even as you deal with this new battle, try to take a little time out each and every day to get away from it. Maybe light a candle, listen to some soothing music, and try to relax and feel all of our warm thoughts and prayers surrounding you. Love, Bill
|
Re: Bad MRI.Liver Met
Michka,
I am back with news from the follow up visit with the interventional radiologist. But...first of all....I am so, so sorry that the post regarding resection vs. cryoablation may have introduced some frightening #s. I didn't realize how much I IGNORE those statistics, because we are all proving them wrong. I have personally struggled with the decision of whether to continue to freeze the met or pursue a resection., thus the reason for the article. So...here are some encouraging words from my radiologist....yours will be much better because when my tumor returns it somehow gets to 3 cm. very quickly. You are in a fantastic position with a single 18mm met!!!! The met is very small which is good. Do demand a biopsy. Since the Drs. will be poking around in there anyhow, it is important to confirm exactly what they are dealing with. Even though I've had 3 mets, the Drs. double check it each time. My original tumor was in the left lobe of the liver, it returned the first time (again in the left lobe) and we froze it. The radiologist used a single probe to freeze a reasonable margin. When it surfaced again (the most recent time), it surfaced next to the earlier tumor. So, the radiologist believes there was a portion of the tumor that wasn't frozen. The 2nd time he used 2 probes and froze an extensive margin. He was optimistic that between chemo and herceptin, the cancer is not spreading. I was concerned that I would be too optimistic. But...in his words!! There is reason to be optimistic. I did express concern that if it surfaces a 3rd time, in the left lobe of the liver and no where else....am I missing an opportunity to be done with this. He thought that was a very reasonable question and is going to talk to my Onc. about a potential liver resection. The radiolgoist does not perform this procedure, I would have to locate a surgeon. If this is the course of action, I will be back to this site to locate the best laproscopic liver surgeon in the U.S. I am not comfortable that there is someone experienced enough in Denver. Michka, with such a small, single met there is reason to be very very optimisitic. Although it sounds quite expensive, it is critical to receive the best care possible with the most experienced Drs. Have you finalized the decision to go with the resection? It sounded like you have. I will be thinking and praying for you, so if you see this post, please let me know that date so we can check in on you. Lots of love sister.....Lori |
| All times are GMT -7. The time now is 11:01 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021